#NewAseBioMember | “AseBio is a pivotal networking platform for companies in the biotechnology sector”

AseBio. What does your company's work bring to the table and what is its strength?

José del Corral. KeyZell introduces an innovative combination of new therapies and advanced artificial intelligence technologies to the field of oncology. Our goal is to significantly improve current cancer treatments by providing more effective and less toxic solutions for patients. In the therapeutic area, we highlight our main drug, LZ-167, which has shown high efficacy in preclinical trials. This drug not only combats the growth of cancer cells but also minimizes side effects, thus improving the quality of life for patients.

At KeyZell, we go beyond developing innovative drugs. We have also created two advanced artificial intelligence systems: the Oncology Precision System (O.P.S.), a disruptive platform based on machine learning that helps oncologists predict the best treatment with the highest five-year survival rate, and the Oncology Diagnostic System (O.D.S.), a platform that uses deep learning to enhance cancer diagnosis accuracy through imaging, achieving a precision of 93%.

We have established strategic collaborations in key markets through our subsidiaries in the United Kingdom, Australia, Thailand, and Mexico, facilitating clinical trials and market access, thereby accelerating the availability of our treatments. Additionally, we have a senior management team with extensive international experience in pharmacology, regulation, cancer research, and business management, enabling us to tackle complex challenges and develop effective solutions.

In summary, KeyZell brings to the field of oncology a unique combination of innovative therapies and advanced technologies, supported by a highly qualified team and a solid business strategy. Our strength lies in our continuous ability to innovate, protect our inventions, and establish strategic alliances that allow us to bring our solutions to a global audience, thereby improving cancer treatment and patients' quality of life.

AseBio. What is AseBio for you?

José del Corral. AseBio is a pivotal networking platform for companies in the biotechnology sector, enabling us to gain deeper insights into industry needs, regulations, and requirements. Additionally, it enhances our company's visibility, facilitating the identification of technological partners, securing funding, and disseminating our clinical results.

AseBio. When did you first hear about AseBio?

José del Corral. At the Madrid Health Entrepreneurship Forum in 2023.

AseBio. What do you expect from being part of an association like AseBio?

José del Corral. As the CEO of KeyZell, being part of an association like AseBio offers us several strategic advantages. We expect this collaboration to strengthen our connections within the biotechnology industry, facilitating access to updated knowledge about sector needs, regulations, and specific requirements.

Furthermore, AseBio provides us with an essential platform to increase KeyZell's visibility. Through this association, we aim to identify and establish partnerships with key technological partners, access new funding opportunities, and disseminate our clinical findings to a wider audience. In summary, we anticipate that our membership in AseBio will boost our capacity for innovation and expansion, thereby contributing to our goal of improving oncological treatments and patients' quality of life.

AseBio. What is the biggest challenge facing the biotech sector (or your company)?

José del Corral. The greatest challenge for the biotech sector and KeyZell is to continue driving innovation to develop more effective and accessible treatments for complex diseases like cancer. This involves overcoming regulatory, financial, and scientific hurdles, as well as the need to establish strategic partnerships and collaborations to advance research and development of new therapies. For KeyZell specifically, the challenge lies in demonstrating the efficacy and safety of our products, overcoming regulatory hurdles in multiple markets, and ensuring equitable access to our therapies for those who need them most.